Continuous subcutaneous infusion of compound oxycodone for the relief of dyspnea in patients with terminally ill cancer: a retrospective study.
Pain and dyspnea are the most prevalent and distressing symptoms in patients with terminally ill cancer. Evidences have accumulated for the effects of morphine on dyspnea, whereas little is known about the effects of oxycodone on dyspnea. We investigated the effectiveness of oxycodone for dyspnea in patients with terminally ill cancer. The injectable form of compound oxycodone (iOC) containing hydrocotarnine was administered continuously via subcutaneous route. We administered iOC to 136 patients. The effect on dyspnea was less conspicuous than pain, yet iOC was effective for dyspnea with varying degrees. None of the adverse effects observed were serious. These results suggest that continuous subcutaneous administration of oxycodone could be one of the reasonable alternatives in the management of dyspnea in patients with terminally ill cancer.
The Palliative Care Unit, Tokyo Kosei-Nenkin Hospital, Tokyo, Japan. kawabata@tkn-hosp.gr.jp
Masahiro
M
Kawabata
Keisuke
K
Kaneishi
D000368:Aged; D000369:Aged, 80 and over; D004417:Dyspnea / Q000188:drug therapy*; D005260:Female; D006801:Humans; D055104:Infusions, Subcutaneous; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy; D010098:Oxycodone / Q000008:administration & dosage / Q000627:therapeutic use*; D059408:Pain Management / Q000379:methods; D012189:Retrospective Studies; D013727:Terminal Care / Q000379:methods*; D016896:Treatment Outcome
D010098:Oxycodone